Can-Fite BioPharma American Depositary Shares
CANF
6 hedge funds and large institutions have $1.5M invested in Can-Fite BioPharma American Depositary Shares in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
7% less capital invested
Capital invested by funds: $1.61M → $1.5M (-$106K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$51.5K |
| 2 |
VF
Virtu Financial
New York
|
+$20.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$30.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$10.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TAM
1
Taylor Asset Management
Toronto,
Ontario, Canada
| $1.35M | – | – | – |
|
|
2
Morgan Stanley
New York
| $70K | +$51.5K | +10 | +250% |
|
|
PVH
3
Psagot Value Holdings
Tel Aviv,
Israel
| $23K | -$30.9K | -6 | -55% |
|
|
RJA
4
Raymond James & Associates
St Petersburg,
Florida
| $21K | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| $20K | -$10.3K | -2 | -33% |
|
|
VF
6
Virtu Financial
New York
| $19K | +$20.6K | +4 | New |
|
|
PCM
7
Prelude Capital Management
New York
| $2K | – | – | – |
|
8
UBS Group
Zurich,
Switzerland
| $2K | – | – | – |
|
CANF Hedge Fund Activity: Q3 2017 in Review
6 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q3 2017, worth a combined $1.5M — down 6.6% from $1.61M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CANF positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $51.5K. The largest seller was Psagot Value Holdings, cutting an estimated $30.9K.
- 6 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $1.5M of Can-Fite BioPharma American Depositary Shares stock for Q3 2017, down 6.6% quarter-over-quarter.
- 1 fund opened new Can-Fite BioPharma American Depositary Shares positions in Q3 2017 and 0 closed out, a net change of +1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q3 2017 was Morgan Stanley, an estimated $51.5K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q3 2017 was Psagot Value Holdings, an estimated $30.9K sold.
Based on aggregated 13F filings for Q3 2017.